Hims & Hers Health, Inc. (HIMS) Stock

Hims & Hers Health, Inc. (HIMS) is a Healthcare stock trading at $31.85 (as of 2026-08-20), with a market capitalization of $7.38B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Hims & Hers Health, Inc. operates an online and mobile health platform that links customers with licensed healthcare professionals for medical consultation and ongoing care, including subscription-based prescription medication. It also sells health and wellness products—such as OTC drugs and devices and categories including skincare, hair care, and sexual health—directly to consumers and through wholesale partners.

Understand Hims & Hers Health, Inc.: how it makes money

Hims & Hers Health runs a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals, and it makes money by selling health and wellness products and services on its websites and mobile app, including recurring prescription medication and ongoing care.

Because the company delivers recurring prescription medication and ongoing care through its telehealth platform, its profit model depends on how many subscription patients it keeps (ending subscriptions and retention) and whether it continues adding net new subscribers.

Revenue by segment (latest quarter)
US	$0.5B
Int	$0.1B

Business quality (Weak): Revenue is sizable and gross margin is strong, but the latest quarter shows an operating loss, so investors should focus on whether subscriber growth and retention can translate into improved operating profitability.

Bull case

Large and growing subscription base: The company reported Ending Subscriptions of 991,000 and Net New Subscribers Added of 30,000 in the latest quarter.
Retention indicators are strong: Long-Term Customer Retention and Online Revenue Retention are both 85%.
Provider enablement appears scalable: Provider Network Size is 1,500, supporting ongoing care delivered through the platform.
Platform personalization is widely used: Subscribers Using Personalized Treatment is 1,600,000, and 65% of subscribers have at least one personalized solution.

Bear case

Operating profitability is currently negative: Operating margin is -12.9% in the latest quarter, so costs have not been matched to scale yet.
Business is still concentrated geographically: United States revenue is 0.53B versus 0.08B for International revenue, so results may be sensitive to changes in the US market.
Growth and revenue depend on subscriber dynamics: The profit model relies on continuing to add net new subscribers and maintaining retention, since the business includes recurring medication and ongoing care.
Use of personalization could reflect treatment intensity and economics: Personalized treatment adoption is 65% of subscribers, so changes in how patients use personalized solutions could affect overall performance.

Valuation — source: SEC EDGAR (first-party)
Price	$31.85
Market Cap	$7.38B
Price / Book	22.78
Price / Sales	2.87
FCF Yield	4.0%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$2.35B
Net Margin	5.5%
Revenue Growth (YoY)	59.0%
EPS Growth (YoY)	-1.7%
FCF Growth (YoY)	-71.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	4.44 (safe)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.6
Industry P/E (Healthcare Services)	25.3

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($679.46M)
Institutional Holders Tracked	10
Congressional Trades (recent)	1

Company
Sector	Healthcare
Industry	Healthcare Services
CEO	Andrew Dudum
Employees	1,637
Country	US
IPO Date	2019-09-13

Related Companies (Business model: Consumer Subscription Content (Streaming, News, Audio); 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.